Literature DB >> 32476899

Case Study: Cardiac sarcoidosis resolved with Mycobacterium avium paratuberculosis antibiotics (MAP).

Branko G Celler1.   

Abstract

Background: The author presents a clinical history and personal case study following his diagnosis of inactive sarcoidosis in 2004, followed by an acute episode of cardiac sarcoidosis (CS) in 2012 which resulted in complete heart block, cardiac myopathy, heart failure and insertion of an implantable cardioverter defibrillator (ICD) pacemaker.
Methods: Following a detailed review of the clinical and scientific literature he concluded that sarcoidosis may be a mycobacterial infection and could be treated with anti-MAP antibiotic regime (1) developed to treat Crohn's disease. Findings: After successful culture and identification of viable MAP in his blood, treatment with the MAP antibiotic regime for one year led to complete metabolic resolution of the previously avid cardiac sarcoidosis and no PET evidence of any metabolically active sarcoidosis anywhere. Such reversal of cardiac sarcoidosis has never previously been reported. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 171-177). Copyright:
© 2018.

Entities:  

Keywords:  MAP; antibiotics; cardiac sarcoidosis; hypercalciuria; mycobacteria

Year:  2018        PMID: 32476899      PMCID: PMC7170090          DOI: 10.36141/svdld.v35i2.6769

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  27 in total

Review 1.  Evidence for mycobacteria in sarcoidosis.

Authors:  Isaac Brownell; Francisco Ramírez-Valle; Miguel Sanchez; Stephen Prystowsky
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-09       Impact factor: 6.914

2.  Calcium metabolism in sarcoidosis and its clinical implications.

Authors:  M Conron; C Young; H L Beynon
Journal:  Rheumatology (Oxford)       Date:  2000-07       Impact factor: 7.580

3.  Calcium oxalate and iron accumulation in sarcoidosis.

Authors:  A J Ghio; V L Roggli; T P Kennedy; C A Piantadosi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2000-06       Impact factor: 0.670

4.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study.

Authors:  Riina Kandolin; Jukka Lehtonen; Juhani Airaksinen; Tapani Vihinen; Heikki Miettinen; Kari Ylitalo; Kari Kaikkonen; Suvi Tuohinen; Petri Haataja; Tuomas Kerola; Jorma Kokkonen; Markus Pelkonen; Päivi Pietilä-Effati; Seppo Utrianen; Markku Kupari
Journal:  Circulation       Date:  2014-12-19       Impact factor: 29.690

5.  Mechanisms of Stone Formation.

Authors:  Vishal N Ratkalkar; Jack G Kleinman
Journal:  Clin Rev Bone Miner Metab       Date:  2011-12

6.  Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy.

Authors:  J E Gottlieb; H L Israel; R M Steiner; J Triolo; H Patrick
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

Review 7.  What causes sarcoidosis?

Authors:  David R Moller; Edward S Chen
Journal:  Curr Opin Pulm Med       Date:  2002-09       Impact factor: 3.155

8.  Use of highly specific DNA probes and the polymerase chain reaction to detect Mycobacterium paratuberculosis in Johne's disease.

Authors:  P H Vary; P R Andersen; E Green; J Hermon-Taylor; J J McFadden
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

Review 9.  Corticosteroids in Sarcoidosis.

Authors:  Marc A Judson
Journal:  Rheum Dis Clin North Am       Date:  2015-10-26       Impact factor: 2.670

Review 10.  The "mystery" of cutaneous sarcoidosis: facts and controversies.

Authors:  G Tchernev; J C Cardoso; A A Chokoeva; S B Verma; C Tana; J Ananiev; M Gulubova; S Philipov; N Kanazawa; P Nenoff; T Lotti; U Wollina
Journal:  Int J Immunopathol Pharmacol       Date:  2014 Jul-Sep       Impact factor: 3.219

View more
  2 in total

Review 1.  Mycobacterium paratuberculosis zoonosis is a One Health emergency.

Authors:  Coad Thomas Dow; Briana Lizet Alvarez
Journal:  Ecohealth       Date:  2022-06-02       Impact factor: 4.464

Review 2.  Warm, Sweetened Milk at the Twilight of Immunity - Alzheimer's Disease - Inflammaging, Insulin Resistance, M. paratuberculosis and Immunosenescence.

Authors:  Coad Thomas Dow
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.